Answers are grounded in this paper and cite their sources.
Develops a screening framework for predicting peptide inhibitors in food proteins, suggesting a new method to combat neurodegenerative disorders.
Prolyl endopeptidase (PEP) is a therapeutic target for neurodegenerative disorders, yet systematic approaches for discovering PEP inhibitory peptides from food proteins remain limited. This study developed a four-rule proline-based screening framework─evaluating proline presence (A1), hydrophobic–proline motifs (A2), consecutive proline patterns (A3), and overlap with known inhibitors (A4)─and applied it to 243 food proteins across five enzyme treatments via in silico hydrolysis. Fourteen candidate peptides were synthesized and validated in vitro (IC50 = 2.12–68.50 μM), with A1 showing strong correlation with inhibitory potency (r = 0.831, p < 0.001). Molecular dynamics, Molecular Mechanics Poisson–Boltzmann Surface Area (MM-PBSA), and quantum mechanical analyses revealed a peptide-length confounding effect on binding energy and demonstrated that potency depends on concentrated, high-quality interactions at the catalytic site rather than total contact extent. This framework provides a practical prioritization strategy for identifying PEP inhibitory peptides from food protein hydrolysates.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: